Kytopen’s Post

Are you at #ATW24? Don't miss Aaron Dulgar-Tulloch's presentation on collaboration for allogeneic cell therapy industrialization with experts from Bayer, Takeda, LIS BioConsulting, and Cartesian Therapeutics. See the video where he previously shared a 'critical, defining moment' in autologous CAR T #celltherapy applications for #cancer patients. When can we expect that moment for allogeneic therapies? What is standing in the way? https://lnkd.in/gmWvNeHX #advancedtherapiesweek #cellandgenetherapy #genomicmedicine

There are many ways to establish 3D organoid cultures embedded in the tumor microenvironment (TME). Here we illustrate a workflow for establishing a de novo organoid model as a standardized and reproducible model for drug testing, consisting of cancer and non-cancer cell types in the TME. Discover more on our application page linked in the comments below. #cancerresearch #tumormicroenvironment

At Pfizer, we are advancing a deep and diverse pipeline that spans three core scientific modalities to attack cancer from multiple angles, including more than 25 new molecular entities. Today at #ASCO24, we are excited to share updated Phase 1 data for several of our priority pipeline therapies, including an oral presentation on our promising investigational integrin beta-6-directed ADC in #NSCLC, which initiated a Phase 3 trial this year. We’re also sharing updated results for our potential first-in-class KAT6 inhibitor in ER+, HER2- metastatic #breastcancer, which were also published in Nature Medicine. Read more here: https://lnkd.in/gA9Y3QA6

In cancer #drugdiscovery and development, a number of concerning trends persist: rising costs, increasing complexity, and a growing number of drugs failing to progress beyond #clinicaltrials. Research shows just 1 in 10 investigational #cancer drugs make it past Phase 1 trials, spanning 14 years and costing $2.7 billion on average. Dive into our latest thought leadership piece and explore how #biopharma researchers can leverage the right genomic data to accelerate drug development, delivering better treatments faster. Read the article ➡️ https://lnkd.in/e4ppm5xw

Introducing SynAI: an AI-driven cancer drugs synergism prediction platform. Move beyond the time-intensive and cumbersome traditional methods of drug combination screening. SynAI leverages compound SMILE sequences to rapidly identify potential therapeutic combinations, significantly saving costs and enhancing research efficiency. Download our paper to discover the advantages SynAI brings to your research. ➡️ https://bit.ly/41YI0Le #AI #Cancer #DrugDiscovery #DrugScreening #CancerResearch #Biotech #Bioscience

For those of you interested in Knowledge Graphs, you may be interested in hearing about InterVenn’s contributions in the area of glycoscience. One of our glyco-scientists, Dr. Matthew Campbell will be presenting. See link below to register. #glycoproteomics #knowledgegraph #pathwaymapping

Say goodbye to traditional, time-consuming, and complex drug combination screening methods. SynAI harnesses the power of compound SMILE sequences to swiftly pinpoint potential therapeutic combinations, resulting in substantial cost savings and a boost in research productivity. Explore our paper to understand the benefits SynAI can offer to your research. #AI #Cancer #DrugDiscovery #DrugScreening #CancerResearch #Biotech #Bioscience

Discover the transformative applications of tumor organoid drug screening. Rapidly identify lead agents from compound libraries, quantify drug efficacy across diverse models, and optimize combination strategies for personalized cancer therapy. These advanced methods are setting new standards in drug discovery and patient-specific treatment. Learn how these applications are enhancing drug discovery and personalized cancer treatment. Write to us at info@gvrp.in to know more! GV Research Platform (GVRP) is the authorized distributor of Crown Bioscience services in India. For more information: 🌐 Website: www.gvrp.in .......................... #TumorOrganoids #DrugScreening #OncologyResearch #LibraryScreening #EfficacyQuantification #CombinationTherapy #Bioinformatics #CancerResearch #BiotechInnovation

On demand webinar on organoid drug screening! Click below to access. #OncoPro #Oncology #3Dmodeling

🔬 How Does Lonza Manufacture an ADC to Fight Cancer? Excited to share this insightful video that explores the intricate process of manufacturing Antibody-Drug Conjugates (ADCs) by a Contract Development and Manufacturing Organization (CDMO) Lonza ADCs are at the forefront of cancer treatment, combining the targeting ability of antibodies with the cancer-killing power of drugs. Watch the video to understand the sophisticated steps involved, from development to production. 📽️ Watch the full video #CancerResearch #Biotechnology #Lonza #ADCs #CDMO #Innovation #Healthcare #CancerTreatment